Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPARC siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Inhalation, Parenteral
01
Overview
SPARC siRNA refers to small interfering RNA molecules designed to target and silence the expression of Secreted Protein Acidic and Rich in Cysteine (SPARC, also known as osteonectin). SPARC is a matricellular glycoprotein that plays a key role in tissue remodeling, extracellular matrix deposition, cell adhesion, migration, and angiogenesis. Its overexpression is associated with poor prognosis, tumor progression, and metastasis in various cancers (such as breast cancer, melanoma, and gastric cancer), as well as pathological fibrosis in diseases like scleroderma and pulmonary fibrosis. SPARC siRNA mediates the sequence-specific degradation of SPARC mRNA, thereby inhibiting SPARC protein synthesis and suppressing downstream oncogenic and profibrotic pathways in preclinical models.
- Other names
- SPARC small interfering RNAosteonectin siRNA
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on SPARC siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPARC siRNA.